Quantcast

Latest Tositumomab Stories

2013-08-26 23:24:00

In a Breaking News Exclusive, Jamie Reno writes how GSK's spokesperson informed him that Bexxar, a lifesaving cancer drug is being discontinued in February 2014. A 17-year cancer survivor who's been in remission for 13 years because of radio-immunotherapy, Reno discusses the ramifications and reasons behind the cancellation of Bexxar. San Diego, CA (PRWEB) August 26, 2013 According to Jamie Reno, an award-winning correspondent for Newsweek, he received a note from GlaxoSmithKline...

2009-12-08 08:01:00

Long-term Results in both First-line and Refractory Settings Seen in Patients with Non-Hodgkin's Lymphoma PHILADELPHIA, Dec. 8 /PRNewswire/ -- GlaxoSmithKline announced today updated long-term survival data from two Phase II studies of BEXXAR® (tositumomab and iodine I-131 tositumomab) used in either patients with previously untreated cancer of the immune system (follicular lymphoma) or in patients with cancer of the lymphocytes (non-Hodgkin's lymphoma, NHL) that no...

2009-10-12 11:00:00

SAN FRANCISCO, Oct. 12 /PRNewswire/ -- Takeda San Francisco, Inc. announced today that Michael Buckley, Ph.D., has joined the company as vice president of process sciences. Dr. Buckley will be responsible for directing all aspects of the materials supply to support research and prepare for production of therapeutic antibody candidates at Takeda's antibody IND engine and center of excellence for biologics. "Mike brings over 20 years of experience in the biopharmaceutical industry and is...

2008-07-29 09:00:23

PHILADELPHIA, July 29 /PRNewswire-USNewswire/ -- Diagnosed with lymphoma, a deadly cancer of the lymphatic system, award-winning Newsweek journalist Jamie Reno felt stunned and alone. What gave him hope was learning of others' successful battles with the disease. His spirits were lifted and today, eleven years later, Jamie Reno has drawn on his experience with the release of Hope Begins in the Dark, a collection of 50 compelling lymphoma survivors' stories. Featuring inspiring personal...

2005-11-02 13:54:54

NEW YORK (Reuters Health) - New treatments incorporating immunotherapy - strategies that boost the immune system -- have significantly improved overall survival of patients with a blood cancer called follicular lymphoma, according to a new report. Emerging data suggest that for patients with follicular lymphoma "initial treatment choices may matter," Dr. Richard I. Fisher from University of Rochester in New York told Reuters Health. Fisher and colleagues compared outcomes of...

2005-06-20 21:47:54

TORONTO, Canada--Three scientific studies--each highlighting new discoveries in treatment for patients with non-Hodgkin's lymphoma--were announced at the Society of Nuclear Medicine's 52nd Annual Meeting June 18"“22 in Toronto. "Nuclear medicine has a growing role in treating non-Hodgkin's lymphoma," said SNM member Richard L. Wahl, M.D., director of nuclear medicine/PET at the Russell H. Morgan Department of Radiology and Radiological Science. "When nuclear medicine is used earlier in...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related